Here at the Center of Excellence has allowed expert scientists and physicians to combine their efforts to accomplish our mission: finding a cure for multiple myeloma and related diseases
(MGUS, Waldenstrom's Macroglobulenemia, amyloidosis) . In addition to innovative clinical
studies offered to more than 300 multiple myeloma patients, we have launched a major endeavor to address fundamental questions regarding the biology and molecular pathogenesis of multiple myeloma.

We are currently acruing patients to the following trials

SAHA-Velcade NCI in Myeloma

VegF Trap NCI 7521: A Phase 2 Study of VEGF Trap (NSC 724770) in Relapsed and Progressive Multiple Myeloma (MedDRA10028228)

Doved, A Sequential Phase II Trial of the Combination of Bortezomib (VELCADE), Dexamethasone (DECADRON) and Liposomal Doxorubicin (DOXIL) DoVe-D Followed by High Dose Cyclophosphamide in Multiple Myeloma Patients

SGN 40 SG040-0001- A Phase I, Multi-Dose Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma

BM study: Molecular Pathogenesis of Multiple Myeloma. Bone marrow aspiration/ biopsy and Venipuncture

Immunomedics - hLL1 A Phase I/II Study of Immunotherapy with hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients with Multiple Myeloma